Mycobacterium tuberculosis Infections – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23015IDB-L5

Select Item

Empower your strategies with our Mycobacterium tuberculosis Infections – Drugs In Development, 2024 report and make more profitable business decisions.

The group of infections caused by Mycobacterium tuberculosis (M. tuberculosis) are referred to as Mycobacterium tuberculosis infections, which primarily affect the lungs but can also impact other parts of the body. The symptoms include persistent cough, fever, weight loss, and night sweats. Treatment typically involves a combination of antibiotics taken over several months. M. tuberculosis infections remain a significant global health concern, with efforts focused on prevention, early diagnosis, and treatment to control its spread.

The Mycobacterium tuberculosis Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Mycobacterium tuberculosis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mycobacterium tuberculosis Infections and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Mycobacterium tuberculosis Infections
Key Targets
· H+ Transporting Two Sector ATPase ; FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase; Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI; Diacylglycerol Acyltransferase/Mycolyltransferase Ag85A; 23S Ribosomal RNA; Mycobacterium tuberculosis ESAT 6 kDa Early Secretory Antigenic Target; Transmembrane Transport Protein mmpL3; RNA Polymerase; Enoyl [Acyl Carrier Protein] Reductase [NADH] ; and 16S Ribosomal RNA
Key Mechanisms of Action
· Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor; FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase Inhibitor; H+ Transporting Two Sector ATPase Inhibitor; 23S Ribosomal RNA Inhibitor; RNA Polymerase Inhibitor; Transmembrane Transport Protein mmpL3 Inhibitor; Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor; Cell Wall Inhibitor; 16S Ribosomal RNA Inhibitor; and Mycobacterium tuberculosis Cytochrome bc1 Complex Cytochrome b Subunit Inhibitor
Key Routes of Administration
· Oral; Inhalational; Intradermal; Intramuscular; Intravenous; Nasal; Subcutaneous; Parenteral; Intravesical; and Sublingual
Key Molecule Types
· Small Molecule; Subunit Vaccine; Recombinant Vector Vaccine; Live Attenuated Vaccine; Vaccine; Inactivated Vaccine; mRNA Vaccine; Peptide; Monoclonal Antibody; and DNA Vaccine
Major Companies
· Global Alliance for TB Drug Development; GSK plc; Quratis Inc; Vichem Chemie Research Ltd; Collaborations Pharmaceuticals Inc; Chinese Academy of Medical Sciences and Peking Union Medical College; Chongqing Zhifei Biological Products Co Ltd; Evotec SE; Foundation For Neglected Disease Research; and NovoBiotic Pharmaceuticals LLC

Scope

  • Therapeutics in Development: Covering 256 molecules, with 156 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Mycobacterium tuberculosis Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Mycobacterium tuberculosis Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mycobacterium tuberculosis Infections treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Abera Bioscience AB
AdjuTec Pharma AS
Agency for Science
Technology and Research
Akagera Medicines Inc
Albert Einstein College of Medicine
Alopexx Inc
Archivel Farma SL
Astellas Pharma Inc
AstraZeneca Plc
Atomwise Inc
Austrianni GmbH
Bill & Melinda Gates Medical Research Institute
BioLingus AG
BioNTech SE
Bioversys AG
Bristol-Myers Squibb Co
Brown University
Butantan Institute
California Institute for Biomedical Research
CanSino Biologics Inc
Central Drug Research Institute
Centre d'Immunologie et des Maladies Infectieuses Paris
Changzhou Yinsheng Pharmaceutical Co Ltd
Chengdu Keen Biotechnology Co Ltd
Chinese Academy of Medical Sciences and Peking Union Medical College
Chongqing Zhifei Biological Products Co Ltd
Collaborations Pharmaceuticals Inc
Colorado State University
Consegna Pharma Inc
Creighton University
Crestone Inc
Daiichi Sankyo Co Ltd
Dartmouth-Hitchcock Medical Center
Demuris Ltd
Eisai Co Ltd
Eli Lilly and Co
Emory University School of Medicine
Enyo Pharma SA
EpiVax Inc
Evoq Nano Inc
Evotec SE
Exscientia Plc
Eyam Vaccines and Immunotherapeutics Ltd
EyeGene Inc
Fimbrion Therapeutics Inc
Foundation For Neglected Disease Research
Gamaleya Federal Research Center of Epidemiology and Microbiology
GC Biopharma Corp
Genexine Inc
GENUONE Sciences Inc
George Washington University
Global Alliance for TB Drug Development
Globeimmune Inc
Griffith University
GSK plc
Guangzhou Egg Biotechnology Co Ltd
HanaVax Inc
Harvard University
Helmholtz Centre for Infection Research
Hsiri Therapeutics LLC
ILiAD Biotechnologies LLC
ImCheck Therapeutics SAS
Immodulon Therapeutics Ltd
Immunitor Inc
ImmunoBiology Ltd
Infectex
Innovare R & D SA De CV
International AIDS Vaccine Initiative Inc
Jiangsu Recbio Technology Co Ltd
Johns Hopkins University
Johns Hopkins University School of Medicine
Johnson & Johnson
Kangzhong Beijing Biological Technology Co Ltd
Korea Research Institute of Chemical Technology
L2 Diagnostics LLC
Lead Discovery Center GmbH
LegoChem Biosciences Inc
LifeArc
Linnane Pharma AB
Longhorn Vaccines and Diagnostics LLC
Ludwig-Maximilians-University Munich
Massey University
Medicines Development for Global Health Ltd
Merck & Co Inc
MetalloPharm LLC
Microbiotix Inc
Moderna Inc
Monash University
Mountain Valley MD Holdings Inc
Mycosynthetix Inc
Nearmedic Plus
NES Biotechnology Co Ltd
Neuro Horizon Pharma LLC
NovoBiotic Pharmaceuticals LLC
Nykode Therapeutics ASA
Oak Therapeutics Inc
Opal Biosciences Ltd
Otsuka Pharmaceutical Co Ltd
Pai Life Sciences Inc
Palacky University Olomouc
Palisades Therapeutics
Pasteur Institute
Pathens Inc
PDS Biotechnology Corp
PeptiDream Inc
Pfizer Inc
Pharmapraxis
Pharmasyntez
Piramal Pharma Ltd
Primetime Life Sciences LLC
Princeton University
Protibea Therapeutics Inc
Purdue University
Quratis Inc
QureTech Bio AB
Qurient Co Ltd
Research Institute of Influenza
Royal College of Surgeons Ireland
Rutgers The State University of New Jersey
Sanofi
Saurashtra University
Scientific Center for Anti-Infectious Drugs
Sentan Pharma Inc
Seoul National University
Sequella Inc
Serum Institute of India Pvt Ltd
Shanghai H&G Biotech
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai Jiatan Pharmaceutical Technology Co Ltd
Shanghai Public Health Clinical Center
Sichuan University
Southwest University
SPbNIIVS FMBA of Russia
Spero Therapeutics Inc
Sphaera Pharma Pte Ltd
SpinCeutica Inc
St. George's University of London
St. George’s University
Standigm Inc
Statens Serum Institut
Stony Brook University
Target Medicals
Tarn Biosciences Inc
Technical University of Munich
Texas Biomedical Research Institute
Texas Tech University Health Sciences Center
The Broad Institute Inc
The Fifth People's Hospital of Suzhou
The Scripps Research Institute
The University of Adelaide
The University of British Columbia
The University of Manchester
Thirty Respiratory Ltd
Tibet Rhodiola Pharmaceutical Holding Co Ltd
TVAX Biomedical Inc
Tydock Pharma Srl
UAB Minority Health and Health Equity Research Center
Univeristy of Zaragoza
University College London
University of Auckland
University of Cape Town
University of Central Florida
University of Dundee
University of Georgia
University of Kansas
University of Kentucky
University of Milan
University of Nebraska Medical Center
University of Oxford
University of Queensland
University of Tennessee Research Foundation
University of Toledo
University of Wisconsin Madison
University of Zurich
Uvax Bio LLC
Vanderbilt University
Vaxil Bio Therapeutics Ltd
Vaxinano SE
Vaxine Pty Ltd
Vichem Chemie Research Ltd
Vir Biotechnology Inc
Wuhan University
Zata Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Mycobacterium tuberculosis Infections reports
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, February 2026
$2,950 | March 2026
Pharmaceuticals
New
Precision and Personalized Medicine - Advanced Therapeutics: Strategic Intelligence
$3,450 | February 2026
Pharmaceuticals
New
Human Immunodeficiency Virus (HIV) Infections (AIDS): Global Clinical Trials Review,…
$3,450 | February 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Mycobacterium tuberculosis Infections – Drugs In Development, 2024 in real time.

  • Access a live Mycobacterium tuberculosis Infections – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more